138 related articles for article (PubMed ID: 9822717)
1. Interactions of p62(dok) with p210(bcr-abl) and Bcr-Abl-associated proteins.
Bhat A; Johnson KJ; Oda T; Corbin AS; Druker BJ
J Biol Chem; 1998 Nov; 273(48):32360-8. PubMed ID: 9822717
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine phosphorylation of p62dok by p210bcr-abl inhibits RasGAP activity.
Kashige N; Carpino N; Kobayashi R
Proc Natl Acad Sci U S A; 2000 Feb; 97(5):2093-8. PubMed ID: 10688886
[TBL] [Abstract][Full Text] [Related]
3. Molecular cloning and characterization of p56dok-2 defines a new family of RasGAP-binding proteins.
Di Cristofano A; Carpino N; Dunant N; Friedland G; Kobayashi R; Strife A; Wisniewski D; Clarkson B; Pandolfi PP; Resh MD
J Biol Chem; 1998 Feb; 273(9):4827-30. PubMed ID: 9478921
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel member of the DOK family that binds and modulates Abl signaling.
Cong F; Yuan B; Goff SP
Mol Cell Biol; 1999 Dec; 19(12):8314-25. PubMed ID: 10567556
[TBL] [Abstract][Full Text] [Related]
5. p62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells.
Carpino N; Wisniewski D; Strife A; Marshak D; Kobayashi R; Stillman B; Clarkson B
Cell; 1997 Jan; 88(2):197-204. PubMed ID: 9008160
[TBL] [Abstract][Full Text] [Related]
6. p62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl).
Di Cristofano A; Niki M; Zhao M; Karnell FG; Clarkson B; Pear WS; Van Aelst L; Pandolfi PP
J Exp Med; 2001 Aug; 194(3):275-84. PubMed ID: 11489947
[TBL] [Abstract][Full Text] [Related]
7. SHP-1 regulation of p62(DOK) tyrosine phosphorylation in macrophages.
Berg KL; Siminovitch KA; Stanley ER
J Biol Chem; 1999 Dec; 274(50):35855-65. PubMed ID: 10585470
[TBL] [Abstract][Full Text] [Related]
8. p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene.
Salgia R; Pisick E; Sattler M; Li JL; Uemura N; Wong WK; Burky SA; Hirai H; Chen LB; Griffin JD
J Biol Chem; 1996 Oct; 271(41):25198-203. PubMed ID: 8810278
[TBL] [Abstract][Full Text] [Related]
9. SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL.
Sattler M; Verma S; Pride YB; Salgia R; Rohrschneider LR; Griffin JD
J Biol Chem; 2001 Jan; 276(4):2451-8. PubMed ID: 11031258
[TBL] [Abstract][Full Text] [Related]
10. Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation.
Heaney C; Kolibaba K; Bhat A; Oda T; Ohno S; Fanning S; Druker BJ
Blood; 1997 Jan; 89(1):297-306. PubMed ID: 8978305
[TBL] [Abstract][Full Text] [Related]
11. The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells.
Ilaria RL; Van Etten RA
Blood; 1995 Nov; 86(10):3897-904. PubMed ID: 7579359
[TBL] [Abstract][Full Text] [Related]
12. CRKL binding to BCR-ABL and BCR-ABL transformation.
Kolibaba KS; Bhat A; Heaney C; Oda T; Druker BJ
Leuk Lymphoma; 1999 Mar; 33(1-2):119-26. PubMed ID: 10194128
[TBL] [Abstract][Full Text] [Related]
13. PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl.
Jain SK; Susa M; Keeler ML; Carlesso N; Druker B; Varticovski L
Blood; 1996 Sep; 88(5):1542-50. PubMed ID: 8781408
[TBL] [Abstract][Full Text] [Related]
14. The SH2-containing adapter protein GRB10 interacts with BCR-ABL.
Bai RY; Jahn T; Schrem S; Munzert G; Weidner KM; Wang JY; Duyster J
Oncogene; 1998 Aug; 17(8):941-8. PubMed ID: 9747873
[TBL] [Abstract][Full Text] [Related]
15. A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells.
Wisniewski D; Strife A; Swendeman S; Erdjument-Bromage H; Geromanos S; Kavanaugh WM; Tempst P; Clarkson B
Blood; 1999 Apr; 93(8):2707-20. PubMed ID: 10194451
[TBL] [Abstract][Full Text] [Related]
16. Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia.
de Jong R; ten Hoeve J; Heisterkamp N; Groffen J
J Biol Chem; 1995 Sep; 270(37):21468-71. PubMed ID: 7545163
[TBL] [Abstract][Full Text] [Related]
17. Cellular interactions of CRKL, and SH2-SH3 adaptor protein.
ten Hoeve J; Kaartinen V; Fioretos T; Haataja L; Voncken JW; Heisterkamp N; Groffen J
Cancer Res; 1994 May; 54(10):2563-7. PubMed ID: 8168080
[TBL] [Abstract][Full Text] [Related]
18. Identification of residues in GTPase-activating protein Src homology 2 domains that control binding to tyrosine phosphorylated growth factor receptors and p62.
Marengere LE; Pawson T
J Biol Chem; 1992 Nov; 267(32):22779-86. PubMed ID: 1385407
[TBL] [Abstract][Full Text] [Related]
19. Tandem SH2 binding sites mediate the RasGAP-RhoGAP interaction: a conformational mechanism for SH3 domain regulation.
Hu KQ; Settleman J
EMBO J; 1997 Feb; 16(3):473-83. PubMed ID: 9034330
[TBL] [Abstract][Full Text] [Related]
20. Downstream of kinase, p62(dok), is a mediator of Fc gamma IIB inhibition of Fc epsilon RI signaling.
Ott VL; Tamir I; Niki M; Pandolfi PP; Cambier JC
J Immunol; 2002 May; 168(9):4430-9. PubMed ID: 11970986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
